SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) today announced that an investigator-sponsored and funded clinical study evaluating Cytori’s cell therapy as a potential treatment for limited and diffuse cutaneous systemic sclerosis (scleroderma) has been approved to begin in France by the National Agency for the Safety of Medicines and Health Products (ANSM, formerly AFSSAPS). The study will be conducted by Professor Guy Magalon, M.D., Chief of the Division of Plastic Surgery and Professor of Universities, at H?pital de la Conception, AP-HM Marseille, France, Professor Brigitte Granel, M.D., Department of Internal Medicine of Hospital Nord and Professor of Universities, and Professor Florence Sabatier, M.D., Head of the Department of Cell Therapy.
